Rapid immunochromatographic test for the detection of SARS-COV-2 antibodies
By following the pandemic situation and using our many years of experience in the pharmaceutical and medical market, we are committed to providing our clients with the necessary personal protective equipment and products.
In response to numerous inquiries, we have introduced to our offer:
RAPID IMMUNOCHROMATOGRAPHIC TEST RAPID TEST SARS-COV-2 IGG / IGM – CASSETTE TEST FOR THE PRESENCE OF CORONAVIRUS SARS-COV-2 AMP ANTIBODIES
Effectiveness of the test:
Test sensitivity: 95,7%
Specificity of the test: 97,3%
Total accuracy: 96,0%
Test sensitivity: 91.8 %
Specificity of the test: 96.4 %
Total accuracy: 95.0 %
IgG antibodies show that the person had recently contact with the antigen (has antibodies)
IgM antibodies indicate the presence of antigen
The quickest way is to detect antibodies which level changes quickly in response to the antigen. This can be shown by the SARS-CoV-2 Cassette.
Test The test is performed by applying the collected sample (10 μl of serum and plasma or 1 drop (approx. 20 μl, most simply from a fingertip) of venous whole blood) onto the sample well of the test cassette using the disposable applicator provided in the kit. The test result is presented after 10-15 minutes as colored lines in the cassette control line region.
IgM antibodies can be detected by testing within 7 days after initial infection or within 3 days of onset of symptoms.
In the case of suspected infection with the SARS-CoV-2 coronavirus, it is necessary to verify a positive test result by a medical professional specialist as soon as possible.
- The test is an in vitro diagnostic medical device, intended for use by qualified medical professionals only.
- Meets the requirements of Directive 98/79 / EC relating to medical devices used for in vitro diagnosis.
- Manufacturer: AMEDA Labordiagnostik GmbH Krenngasse 12, 8010 Graz, Austria.
- Espefa in cooperation with AMP is the exclusive representative of the manufacturer on the Polish market.
- 1 pack contains 25 tests. There is 1 buffer in each pack
Serological tests are very popular around the world as they indicate whether a person has been exposed to the pathogen and whether there is an ongoing infection.
During an epidemic, when non-medical facilities are struggling with outbreaks of infections among employees, serological tests can be helpful in ensuring continuity of work.Epidemiological studies conducted among staff may identify who is immune to the Coronavirus, since they have already had the disease, and who is currently ill (in this case, urgent molecular testing is necessary to evaluate for active SARS-CoV-2 infection; until the active infection is not ruled out, the worker should not work and be placed in isolation).
The most important task, however, will be to quickly detect people who pose a risk of infection to the staff and their immediate separation.
Our AMP Rapid Test SARS-CoV-2 tests by AMEDA Labordiagnostik GmbH have received a positive opinion from the National Reference Center (NRC) at the Pasteur Institute in France.
Our tests have been included on the published list of SARS-CoV-2 antibodies detection tests available on the market without any contradictions. Which is important, as in many other tests shown there NCR found significant diagnostic limitations. Most of them were unsuitabile for the determination of IgM antibodies (comments under the red triangle with an exclamation point).
The list of tests is published on the website of the French Ministry of Health https: /covid-19.sante.gouv.fr/tests
You are welcome to cooperate
Urszula Markowicz-Jureczko, tel.: +48 693 183 450